Differential Effects of RUNX2 on the Androgen Receptor in Prostate Cancer: Synergistic Stimulation of a Gene Set Exemplified by SNAI2 and Subsequent Invasiveness

Changes to androgen signaling during prostate carcinogenesis are associated with both inhibition of cellular differentiation and promotion of malignant phenotypes. The androgen receptor (AR)-binding transcription factor RUNX2 has been linked to prostate cancer progression but the underlying mechanis...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 74; no. 10; pp. 2857 - 2868
Main Authors LITTLE, Gillian H, BANIWAL, Sanjeev K, SCHONES, Dustin E, FRENKEL, Baruch, ADISETIYO, Helty, GROSHEN, Susan, CHIMGE, Nyam-Osor, SUN YOUNG KIM, KHALID, Omar, HAWES, Debra, JONES, Jeremy O, PINSKI, Jacek
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 15.05.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Changes to androgen signaling during prostate carcinogenesis are associated with both inhibition of cellular differentiation and promotion of malignant phenotypes. The androgen receptor (AR)-binding transcription factor RUNX2 has been linked to prostate cancer progression but the underlying mechanisms have not been fully defined. In this study, we investigated the genome-wide influence of RUNX2 on androgen-induced gene expression and AR DNA binding in prostate cancer cells. RUNX2 inhibited the androgen response partly by promoting the dissociation of AR from its target genes such as the tumor suppressor NKX3-1. However, AR activity persists in the presence of RUNX2 at other AR target genes, some of which are cooperatively stimulated by androgen and RUNX2 signaling. These genes are associated with putative enhancers co-occupied by AR and RUNX2. One such gene, the invasion-promoting Snail family transcription factor SNAI2, was co-activated by AR and RUNX2. Indeed, these two transcription factors together, but neither alone stimulated prostate cancer cell invasiveness, which could be abolished by SNAI2 silencing. Furthermore, an immunohistochemical analysis of SNAI2 in archived primary prostate cancer specimens revealed a correlation with the RUNX2 histoscore, and simultaneous strong staining for SNAI2, RUNX2, and AR (but not any pair alone) was associated with disease recurrence. Overall, our findings suggest cooperation between AR and RUNX in the stimulation of oncogenes such as SNAI2, which might be targeted for individualized prostate cancer therapy.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-13-2003